Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARI-0001 in Relapsed/Refractory CD19+ ALL
NCT04778579Phase 2Active, not recruiting
- Start
- May 2021
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ARI-0001 in acute lymphoblastic leukemia (ALL). Started May 2021; status: active, not recruiting.
02
Drugs
ARI-0001
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04778579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04778579.